Clinical Trial: Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07888530) titled 'Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma' on Oct. 15.

Brief Summary: Establishing real-world data of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) treated with Ranicabtagene Autoleucel Injection to evaluate its efficacy and safety.

Study Start Date: Oct. 30

Study Type: OBSERVATIONAL

Condition: B-Cell Non-Hodgkin Lymphoma (NHL)

Intervention: DRUG: Ranicabtagene Autoleucel Injection

Ranicabtagene Autoleucel Injection Autologous genetically modified anti-CD19 CAR-T cells

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hrain Bi...